secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2022-11-21T23:59:59+00:00
Accession:  0000885725-22-000030
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific adopts 2023 annual bonus and performance share programs
-------------------------------------------------------------------------

- 2023 Annual Bonus Plan ties cash incentive to adjusted EPS, global sales (constant currency), ESG scorecard, and quality assessment.
- Bonus pool funding ranges from 0% to 150% of aggregate targets; CEO may adjust unit funding ±10%.
- 2023 rTSR PSP awards RSUs based on three-year TSR vs S&P 500 Healthcare Index (0-200% of target).
- 2023 Organic Net Sales PSP uses three-year organic sales growth vs plan (0-200% of target); replaces prior free cash flow program.
- All awards subject to recoupment policy for misconduct or financial restatement under Dodd-Frank clawback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572522000030/0000885725-22-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572522000030/bsx-20221118.htm
  HTML page:      https://secwatch.observer/filing/0000885725-22-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer